Navigation Links
CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill
Date:3/8/2013

WASHINGTON, March 8, 2013 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) released a statement today on a recent study conducted by American Enterprise Institute fellow Alex Brill and supported by a grant from CHPA. Brill previously served as the chief economist for the U.S. House Committee on Ways and Means from 2002-2007.  His economic policy consulting firm, Matrix Global Advisors, published the study March 4.

With consideration to both the economic costs on the healthcare system and consumers, the study examines the unintended impacts of a prescription-only policy for cold and allergy medicines containing pseudoephedrine (PSE) and finds:

  • Extra doctor visits, contributing $59 million in additional costs to the government, consumers, and private insurance companies in the first year following the policy's implementation;
  • More absenteeism and lost work productivity, when the common cold already costs this nation an estimated $25 billion annually in lost productivity;
  • Higher prices for PSE medicines due to the overall cost difference between a prescription-only product and an over-the-counter one;
  • Increased health insurance premiums due to additional doctor visits and higher PSE drug costs;
  • An estimated loss of $219.2 million in state tax revenues over ten years.

"There is no question that certain states struggle with domestic methamphetamine production," said Alex Brill , chief executive officer of Matrix Global Advisors. "However, my analysis left me convinced that the serious economic and social consequences of a prescription requirement, coupled with the dominance of Mexican drug cartels in the American meth market, should give lawmakers pause before pursuing such a policy."

"Recent consumer surveys clearly demonstrate that law-abiding citizens oppose legislation that would force them to consult with a doctor in order to buy the cold and allergy medicines of their choice," said David Spangler , senior vice president, policy and general counsel at CHPA. "This study provides us with a better understanding of the consumer burden by quantifying the economic impact a prescription requirement would have—most importantly  on consumers— but also on businesses and state governments as well."

Editor's note: To access Brill's complete study, visit http://www.matrixglobaladvisors.com/storage/PSE.pdf

CHPA is the 132-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.

chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
2. CHPA Statement on Statewide Indiana Consumer Poll
3. Sonitus Medical Announces Affirmative Update Regarding Bone Conduction Oral Appliances in American Academy of Otolaryngology-Head and Neck Surgery Policy Statement on Implantable Hearing Devices
4. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. CVS Caremark Statement and Response to CMS Action
9. World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
10. STATEMENT OF CHAIRMAN AND CEO GEORGE BARRETT FORTUNE 21 CARDINAL HEALTH REGARDING FISCAL CLIFF
11. PCMA Statement on Essential Health Benefits Proposed Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):